Assess the Oral Bioavailability of New ABT-263 Formulations
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter crossover study to determine the oral
bioavailability of new ABT-263 formulations relative to that of the current ABT-263
formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable
subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors
will be enrolled in this study.